New era for myelofibrosis treatment with novel agents beyond JAK2 -inhibitor monotherapy

[Manouche]

There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment.

acsjournals.onlinelibrary.w...

[merlisa]

Now, only VENETOCLAX one medicine has been on the market, and combined with aza using in the field of chemotherapy for hematological tumors.

How to avoid using these VENETOCLAX and aza to prevent fibrosis from turning to MDS or even leukemia what I'm concerned about.

[cvita71]

Thanks so much Manouche for sharing this link.